A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice

Inclusion Criteria

• •Participants must have one of the following confirmed diagnoses for which atezolizumab is approved in the local SmPC:
• •* Early stage NSCLC following complete resection and platinum-based chemotherapy with a high risk of recurrence and PD-L1 expression on ≥ 50% of TC and with no EGFR-mutant or ALK-positive NSCLC
• •* Metastatic stage NSCLC with PD-L1 expression on ≥ 50% TC or ≥ 10% tumor infiltrating immune cells (IC) and with no EGFR-mutant or ALK-positive NSCLC not previously treated
• •* Extensive-stage small cell lung cancer (ES-SCLC) not previously treated
• •* Advanced or unresectable HCC not previously treated with systemic therapy
• •Should not have received \> 4 prior cycles of IV Atezolizumab